Trial Profile
Multi-Center Registry Trial of EXCEL Rapamycin Biodegradable Polymer Drug-Eluting Stent.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CREATE
- 21 May 2012 Actual end date changed from 31 Dec 2006 to 31 Dec 2007 as reported by Chinese Clinical Trial Register.
- 22 Jun 2009 New source identified and integrated (Chinese Clinical Trial Register).
- 22 Jun 2009 JW Medical Systems added as sponsor, additional lead trial centres identified as reported by Chinese Clinical Trial Register record.